Hoth Therapeutics Starts Preclinical Study For Its Alzheimer's Candidate

Hoth Therapeutics Inc (NASDAQ:HOTH) has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.
The study aims to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer's disease.
Hoth study will also determine if the behavior is improved utilizing HT-ALZ in blocking NK-1Rs.
The designed studies are taking place under a Scientific Research Agreement entered by Hoth in June 2021.
Price Action: HOTH shares are up 3.87% at $1.34 during the market session on the last check Monday.